Asymchem Laboratories (Tianjin) Valuation

Q: What is the Fair Price of 002821 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002821 (CN¥91.25) is trading above our estimate of [[fair value]] (CN¥88.45)

Is 002821 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002821 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002821 (CN¥91.25) is trading above our estimate of fair value (CN¥88.45)

Significantly Below Fair Value: 002821 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002821?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 002821. This is calculated by dividing 002821's market cap by their current preferred multiple.
What is 002821's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

002821 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	24.2x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does 002821's PE Ratio compare to its peers?

The above table shows the PE ratio for 002821 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.2x
600566 Hubei Jumpcan Pharmaceutical	10.6x	12.8%	CN¥29.4b
000513 Livzon Pharmaceutical Group	17.3x	10.7%	CN¥30.9b
002294 Shenzhen Salubris Pharmaceuticals	58.5x	15.5%	CN¥35.7b
600079 Humanwell Healthcare (Group)Ltd	18.3x	13.7%	CN¥35.8b
002821 Asymchem Laboratories (Tianjin)	42.1x	29.9%	CN¥31.5b

Price-To-Earnings vs Peers: 002821 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the peer average (26.2x).

Price to Earnings Ratio vs Industry

How does 002821's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 002821 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the CN Pharmaceuticals industry average (31.2x).

Price to Earnings Ratio vs Fair Ratio

What is 002821's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002821 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	42.1x
Fair PE Ratio	35x

Price-To-Earnings vs Fair Ratio: 002821 is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the estimated Fair Price-To-Earnings Ratio (35x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002821 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥91.25	CN¥94.33 +3.4%	22.9%	CN¥127.80	CN¥59.40	n/a	10
Nov ’25	CN¥81.20	CN¥93.50 +15.2%	24.0%	CN¥127.80	CN¥52.40	n/a	11
Oct ’25	CN¥83.73	CN¥86.07 +2.8%	25.4%	CN¥130.30	CN¥52.40	n/a	11
Sep ’25	CN¥63.67	CN¥90.80 +42.6%	22.6%	CN¥130.30	CN¥56.30	n/a	11
Aug ’25	CN¥74.08	CN¥95.64 +29.1%	21.4%	CN¥135.10	CN¥56.30	n/a	11
Jul ’25	CN¥65.22	CN¥99.43 +52.4%	20.9%	CN¥145.00	CN¥61.00	n/a	11
Jun ’25	CN¥76.69	CN¥99.43 +29.6%	20.9%	CN¥145.00	CN¥61.00	n/a	11
May ’25	CN¥82.65	CN¥99.43 +20.3%	20.9%	CN¥145.00	CN¥61.00	n/a	11
Apr ’25	CN¥87.00	CN¥127.74 +46.8%	25.5%	CN¥184.00	CN¥85.00	n/a	10
Mar ’25	CN¥102.24	CN¥152.54 +49.2%	23.4%	CN¥197.56	CN¥91.40	n/a	9
Feb ’25	CN¥90.72	CN¥159.52 +75.8%	22.7%	CN¥197.56	CN¥91.40	n/a	9
Jan ’25	CN¥116.10	CN¥166.73 +43.6%	18.6%	CN¥197.56	CN¥106.57	n/a	9
Dec ’24	CN¥141.00	CN¥170.73 +21.1%	17.4%	CN¥197.56	CN¥106.57	n/a	9
Nov ’24	CN¥146.21	CN¥170.03 +16.3%	17.6%	CN¥197.56	CN¥106.25	CN¥81.20	9
Oct ’24	CN¥151.70	CN¥155.20 +2.3%	21.5%	CN¥200.30	CN¥100.13	CN¥83.73	9
Sep ’24	CN¥131.67	CN¥155.86 +18.4%	21.6%	CN¥200.30	CN¥100.13	CN¥63.67	9
Aug ’24	CN¥125.79	CN¥159.22 +26.6%	23.2%	CN¥196.74	CN¥100.13	CN¥74.08	9
Jul ’24	CN¥117.86	CN¥167.63 +42.2%	29.8%	CN¥268.60	CN¥100.13	CN¥65.22	9
Jun ’24	CN¥136.02	CN¥175.30 +28.9%	27.2%	CN¥268.60	CN¥100.13	CN¥76.69	8
May ’24	CN¥126.45	CN¥175.97 +39.2%	26.7%	CN¥268.60	CN¥100.13	CN¥82.65	8
Apr ’24	CN¥133.33	CN¥188.15 +41.1%	28.4%	CN¥288.10	CN¥100.13	CN¥87.00	7
Mar ’24	CN¥143.76	CN¥195.53 +36.0%	30.6%	CN¥323.20	CN¥117.42	CN¥102.24	7
Feb ’24	CN¥165.96	CN¥195.03 +17.5%	31.4%	CN¥323.20	CN¥109.49	CN¥90.72	7
Jan ’24	CN¥148.00	CN¥195.03 +31.8%	31.4%	CN¥323.20	CN¥109.49	CN¥116.10	7
Dec ’23	CN¥137.48	CN¥195.03 +41.9%	31.4%	CN¥323.20	CN¥109.49	CN¥141.00	7
Nov ’23	CN¥150.17	CN¥209.29 +39.4%	26.0%	CN¥323.20	CN¥145.70	CN¥146.21	6

Analyst Forecast: Target price is less than 20% higher than the current share price.